Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats.

Cytokine gene transfer using (multiple) intratumoral injections can induce tumor regression in several animal models, but this administration technique limits the use for human gene therapy. In the present studies we describe tumor growth inhibition of established limb sarcomas after a single isolated limb perfusion (ILP) with recombinant adenoviral vectors harboring the rat IL-3 beta gene (IG.Ad.CMV.rIL-3 beta). In contrast, a single intratumoral injection or intravenous administration did not affect tumor growth. Dose-finding studies demonstrated a dose-dependent response with a loss of antitumor effect below 1 x 10(9) IU of IG.Ad.CMV.rIL-3 beta. Perfusions with adenoviral vectors bearing a weaker promoter (MLP promoter) driving the rIL-3 beta gene did not result in antitumor responses, suggesting that the rIL-3 beta-mediated antitumor effect depends on the amount of rIL-3 beta protein expressed by the infected cells. Furthermore, it was shown by direct comparison that ILP with IG.Ad.CMV.rIL-3 beta in the ROS-1 osteosarcoma model is at least as efficient as the established therapy with the combination of TNF-alpha and melphalan. Treatment with IG.Ad.CMV.rIL-3 beta induced a transient dose-dependent leukocytosis accompanied by an increase in peripheral blood levels of histamine. Leukocyte infiltrations were also histopathologically demonstrated in tumors after perfusion. These results demonstrate that ILP with recombinant adenoviral vectors carrying the IL-3 beta transgene inhibits tumor growth in rats and suggest that cytokine gene therapy using this administration technique might be beneficial for clinical cancer treatment.

[1]  S. Libutti,et al.  Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma. , 2002 .

[2]  A. Eggermont,et al.  Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras , 2002, British Journal of Cancer.

[3]  A. Eggermont,et al.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives , 2001, Current oncology reports.

[4]  A. Eggermont,et al.  Isolated Limb Perfusion for Local Gene Delivery: Efficient and Targeted Adenovirus-Mediated Gene Transfer Into Soft Tissue Sarcomas , 2000, Annals of surgery.

[5]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[6]  Y. Tsutsumi,et al.  Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. , 1998, Cancer research.

[7]  T. Hoover,et al.  Cloning and characterization of Planctomyces limnophilus rpoN: complementation of a Salmonella typhimurium rpoN mutant strain. , 1998, Gene.

[8]  A. van der Eb,et al.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. , 1998, Human gene therapy.

[9]  A. Bout,et al.  IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using ‘cracked’ adenoproducer cells , 1998, Gene Therapy.

[10]  T. Potter,et al.  In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. , 1998, The Journal of clinical investigation.

[11]  A. Bout,et al.  Cloning, biological characterization and high-level expression of rat interleukin-3 using recombinant adenovirus: description of a new splicing variant. , 1998, Gene.

[12]  D. Collen,et al.  Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. , 1998, Circulation.

[13]  G. Bieler,et al.  Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ , 1998, Nature Medicine.

[14]  F. Graham,et al.  Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. , 1998, Human gene therapy.

[15]  B. Feig,et al.  Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  J. Hong,et al.  Effects of IL-3 gene expression on tumor response to irradiation in vitro and in vivo. , 1997, Cancer research.

[17]  N. Yang,et al.  Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. , 1997, Human gene therapy.

[18]  A. Bout,et al.  Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene , 1997, Gene Therapy.

[19]  B. Sugarman,et al.  Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. , 1997, Human gene therapy.

[20]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[21]  P. Schlag,et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.

[22]  A. Eggermont,et al.  Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. , 1996, British Journal of Cancer.

[23]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Shastri,et al.  Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Eggermont,et al.  Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat , 1996, The British journal of surgery.

[26]  A. Eggermont,et al.  Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  D. Fraker,et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Gamble,et al.  IL‐3 receptor expression, regulation and function in cells of the Vasculature. , 1996, Immunology and cell biology.

[29]  C. Avezaat,et al.  Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. , 1996, Human gene therapy.

[30]  W. Muller,et al.  Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Gamble,et al.  Interferon-gamma upregulates interleukin-3 (IL-3) receptor expression in human endothelial cells and synergizes with IL-3 in stimulating major histocompatibility complex class II expression and cytokine production. , 1995, Blood.

[32]  L. Zitvogel,et al.  Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. , 1995, Journal of immunology.

[33]  A. Eggermont,et al.  Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) , 1994 .

[34]  J. Mulé,et al.  Experimental and clinical studies of cytokine gene-modified tumor cells. , 1994, Human gene therapy.

[35]  M. Colombo,et al.  Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? , 1994, Immunology today.

[36]  C. Chiang,et al.  Interleukin-3 in gene therapy of cancer. , 1994, Folia biologica.

[37]  A. Douvdevani,et al.  Cytokine-induced tumor immunogenicity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity. , 1993, Immunology letters.

[38]  J. Gamble,et al.  The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Mantovani,et al.  Differential expression of the common β and specific α chains of the receptors for GM-CSF, IL-3, and IL-5 in endothelial cells , 1993 .

[40]  M. Brizzi,et al.  Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells. , 1993, The Journal of clinical investigation.

[41]  A. McAdam,et al.  Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. , 1993, Cancer research.

[42]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Überla,et al.  Interleukin‐4‐mediated tumor suppression in nude mice involves interferon‐γ , 1992, European journal of immunology.

[44]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Blankenstein,et al.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection , 1991, The Journal of experimental medicine.

[46]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[47]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[48]  J. Heeney,et al.  Highly Increased Production of Bone Marrow-Derived Blood Cells by Administration of Homologous Interleukin-3 to Rhesus Monkeys , 1990 .

[49]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[50]  M. Vadas,et al.  Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor show common biological effects and binding characteristics on human monocytes. , 1989, Blood.

[51]  K. Arai,et al.  Human recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3 cause basophil histamine release. , 1988, The Journal of clinical investigation.

[52]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[53]  Yu-Chung Yang,et al.  Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3 , 1986, Cell.

[54]  D. Cohen,et al.  Cloning and expression of the rat interleukin-3 gene. , 1986, Nucleic acids research.

[55]  V. Kindler,et al.  Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Zondervan,et al.  Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats. , 1984, Journal of the National Cancer Institute.

[57]  J. Ihle,et al.  Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. , 1983, Journal of immunology.

[58]  G. Barendsen,et al.  Differences in effectiveness of combined treatments with ionizing radiation and vinblastine, evaluated for experimental sarcomas and squamous cell carcinomas in rats. , 1978, International journal of radiation oncology, biology, physics.

[59]  I. Hutton,et al.  Chemotherapy of sarcomas of the limbs by regional perfusion. , 1977, Annals of surgery.

[60]  M. Slavik,et al.  Chemotherapy of cancer , 1977 .

[61]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.

[62]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.